Angiotech CoSeal
This article was originally published in The Gray Sheet
Executive Summary
U.S. clinical trials for drug-coated version of the polymer vascular surgical sealant are scheduled to begin in 2004, the company says. Angiotech Pharmaceuticals' acquisition of CoSeal developer Cohesion Technologies was completed Feb. 3 (1"The Gray Sheet" Oct. 7, 2002, p. 29). A "premixed" version of the device recently received PMA supplement approval, allowing the sealant to be loaded with an Angiotech pharmaceutical to prevent surgical adhesions. Current CoSeal improvements include easier preparation, a life span increase from 45 minutes to two hours and the ability to be stored at room temperature...